Page 1325 - Hall et al (2015) Principles of Critical Care-McGraw-Hill

2 References

chemotherapy with L-asparaginase in adult patients with acute and G-CSF (CLAG) as induction therapy for patients with
lymphoblastic leukemia or lymphoblastic lymphoma. Use relapsed or refractory acute myeloid leukemia. Leuk Lymphoma.
of supportive coagulation therapy and clinical outcome: the 2000;39:121.
CAPELAL study. Haematologica. 2008;93:1488. 45. Roze des Ordons AL, Chan K, Mirza I, et al. Clinical char-
29. Inthal A, Krapf G, Beck D, et al. Role of the erythropoietin acteristics and outcomes of patients with acute myelogenous
receptor in ETV6/RUNX1-positive acute lymphoblastic leuke- leukemia admitted to intensive care: a case-control study. BMC
mia. Clin Cancer Res. 2008;14:7196. Cancer. 2010;10:516.
30. Jabbour E, Thomas D, Cortes J, et al. Central nervous system 46. Sanz MA, Lo-Coco F. Modern approaches to treating acute
prophylaxis in adults with acute lymphoblastic leukemia: cur- promyelocytic leukemia. J Clin Oncol. 2011;29(5):495-503.
rent and emerging therapies. Cancer. 2010;116:2290. 47. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol
31. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with anthracycline-based consolidation results in high antileu-
with hyper-CVAD, a dose-intensive regimen, in adult acute kemic efficacy and reduced toxicity in newly diagnosed PML/
lymphocytic leukemia. J Clin Oncol. 2000;18:547. RARalpha-positive acute promyelocytic leukemia. PETHEMA
32. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission group. Blood. 1999;94:3015.
induction regimen with intensive consolidation for adults with 48. Sanz MA, Montesinos P. Open issues on bleeding and thrombo-
acute lymphoblastic leukemia: cancer and leukemia group B sis in acute promyelocytic leukemia. Thromb Res. 2010;125(suppl
study 8811. Blood. 1995;85:2025. 2):S51.
33. Leventakos K, Lewis RE, Kontoyiannis DP: Fungal infections 49. Shonkwiler E. Targeting tumor lysis syndrome: new therapeutic
in leukemia patients: how do we prevent and treat them? Clin options. ONS News. 2006;21:49.
Infect Dis. 2010;50:405. 50. Slichter SJ. Evidence-based platelet transfusion guidelines.
34. Levi M, Toh CH, Thachil J, et al. Guidelines for the diagno- Hematology Am Soc Hematol Educ Program. 2007:172.
sis and management of disseminated intravascular coagula- 51. Spivak JL. The anaemia of cancer: death by a thousand cuts. Nat
tion. British Committee for Standards in Haematology. Br J Rev Cancer. 2005;5:543.
Haematol. 2009;145:24. 52. Sternberg DW, Aird W, Neuberg D, et al. Treatment of patients
35. Lowenberg B. Diagnosis and prognosis in acute myeloid with recurrent and primary refractory acute myelogenous leu-
leukemia—the art of distinction. N Engl J Med. 2008;358:1960. kemia using mitoxantrone and intermediate-dose cytarabine: a
36. Machner B, Neppert B, Paulsen M, et al. Pseudotumor cerebri pharmacologically based regimen. Cancer. 2000;88:2037.
as a reversible side effect of all-trans retinoic acid treatment in 53. Thiebaut A, Thomas X, Belhabri A, et al. Impact of pre-
acute promyelocytic leukaemia. Eur J Neurol. 2008;15:e68. induction therapy leukapheresis on treatment outcome in adult
37. Marbello L, Ricci F, Nosari AM, et al. Outcome of hyperleuko- acute myelogenous leukemia presenting with hyperleukocytosis.
cytic adult acute myeloid leukaemia: a single-center retrospec- Ann Hematol. 2000;79:501.
tive study and review of literature. Leuk Res. 2008;32:1221. 54. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia
38. Mato AR, Riccio BE, Qin L, et al. A predictive model for the chromosome-positive acute lymphocytic leukemia with hyper-
detection of tumor lysis syndrome during AML induction CVAD and imatinib mesylate. Blood. 2004;103:4396.
therapy. Leuk Lymphoma. 2006;47:877. 55. Tosi P, Barosi G, Lazzaro C, et al. Consensus conference on
39. Menell JS, Cesarman GM, Jacovina AT, et al. Annexin II and the management of tumor lysis syndrome. Haematologica.
bleeding in acute promyelocytic leukemia. N Engl J Med. 2008;93:1877.
1999;340:994. 56. Vahdat L, Maslak P, Miller WH Jr, et al. Early mortality and
40. Mughal TI, Ejaz AA, Foringer JR, et al. An integrated clinical the retinoic acid syndrome in acute promyelocytic leukemia:
approach for the identification, prevention, and treatment of impact of leukocytosis, low-dose chemotherapy, PMN/RAR-
tumor lysis syndrome. Cancer Treat Rev. 2010;36:164. alpha isoform, and CD13 expression in patients treated with
41. Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in all-trans retinoic acid. Blood. 1994;84:3843.
hyperleucocytic leukaemias: lack of correlation between degree of 57. Vardiman JW, Harris NL, Brunning RD. The World Health
cytoreduction and early mortality rate. Br J Haematol. 1997;98:433. Organization (WHO) classification of the myeloid neoplasms.
42. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 Blood. 2002;100:2292.
study of dasatinib with hyper-CVAD for the frontline treatment 58. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype
of patients with Philadelphia chromosome-positive (Ph+) acute analysis in adult acute lymphoblastic leukemia: the cancer and
lymphoblastic leukemia. Blood. 2010;116:2070. leukemia Group B experience. Blood. 1999;93:3983.
43. Rickles FR, Falanga A, Montesinos P, et al. Bleeding and throm- 59. Wiernik PH, Banks PL, Case DC Jr, et al. Cytarabine plus ida-
bosis in acute leukemia: what does the future of therapy look rubicin or daunorubicin as induction and consolidation therapy
like? Thromb Res. 2007;120(suppl 2):S99. for previously untreated adult patients with acute myeloid
44. Robak T, Wrzesien-Kus A, Lech-Maranda E, et al. Combination leukemia. Blood. 1992;79:313.
regimen of cladribine (2-chlorodeoxyadenosine), cytarabine

Section07-O-ref.indd 2 1/21/2015 11:26:50 AM